Prediction of cardio- and cerebro-vascular events in patients with subclinical carotid atherosclerosis and low HDL-cholesterol

Atherosclerosis

Volumn 200, Issue 2, 2008, Pages 389-395

  Rizzo, Manfredi ^a   Corrado, Egle ^b   Coppola, Giuseppe ^b   Muratori, Ida ^b   Novo, Giuseppina ^b   Novo, Salvatore ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Atherosclerosis; Carotid lesions; HDL cholesterol; Inflammation; Prevention

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE; AGED; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; COLOR ULTRASOUND FLOWMETRY; CONFIDENCE INTERVAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; FOLLOW UP; GENDER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OBESITY; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SMOKING;

EID: 52049083661     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.12.020     Document Type: Article

References (34)

1. National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
2. Grundy S.M., Cleeman J.I., Daniels S.R., et al., American Heart Association, National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
3. Rydén L., Standl E., Bartnik M., et al., The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 28 (2007) 88-136
4. Navab M., Anantharamaiah G.M., Reddy S.T., et al. Mechanisms of disease: proatherogenic HDL-an evolving field. Nat Clin Pract Endocrinol Metab 2 (2006) 504-511
5. Spence D., and Norris J. Infection, inflammation, and atherosclerosis. Stroke 34 (2003) 333-334
6. Corrado E., and Novo S. Role of inflammation and infection in vascular disease. Acta Chir Belg 105 (2005) 567-579
7. Burke G.L., Evans G.W., Riley W.A., et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 26 (1995) 386-391
8. Bots M.L., Moons K.G., Hollander M., et al. Is carotid intima-media thickness useful in cardiovascular disease risk assessment? The Rotterdam Study. Circulation 96 (1997) 1432-1437
9. O'Leary D.H., Polak J.F., Kronmal R.A., et al., Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 340 (1999) 14-22
10. Corrado E., Rizzo M., Tantillo R., et al. Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5 years follow-up study. Stroke 37 (2006) 482-486
11. Murata M., and Ide T. Determination of cholesterol in sub-nanomolar quantities in biological fluids by high-performance liquid chromatography. J Chromatogr 579 (1992) 329-333
12. Montagne P., Laroche P., Cuilliere M.L., Varcin P., and Duheille J. Microparticle-enhanced nephelometric immunoassay for human C-reactive protein. J Clin Lab Anal 1 (1992) 24-29
13. Myers G.L., Rifai N., Tracy R., et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease Application to Clinical and Public Health Practice Report From the Laboratory Science Discussion Group. Circulation 110 (2004) 13 577-578
14. Von Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 17 (1957) 231-237
15. Imperatore G., Riccardi G., Iovine C., Rivallese A., and Vaccaro O. Plasma fibrinogen: a new factor of the metabolic syndrome. a population-based study. Diabetes Care 21 4 (1998) 649-654
16. Pignoli P., Tremoli E., Poli A., Oreste P., and Paoletti R. Intimal plus medial thickness of the arterial wall. A direct measurement with ultrasound imaging. Circulation 74 (1986) 1399-1406
17. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial Hypertension. J Hypertens 2003;21:1011-53.
18. Pasceri V., Chang J., Willerson J.T., and Yeh E.T.H. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102 (2000) 2165-2168
19. Levenson J., Giral P., Razavian M., Gariepy J., and Simon A. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscler Thromb Vasc Biol 15 (1995) 1263-1268
20. Wilhelmsen L., Svardsudd K., Korsan-Bengtsen K., et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 311 (1984) 501-505
21. Woodward M., Lowe G.D., Rumley A., et al. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 97 (1997) 785-797
22. Maresca G., Di Blasio A., Marchioli R., and Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction. Arterioscler Thromb Vasc Biol 19 (1999) 1368-1377
23. Coppola G., Corrado E., Muratori I., et al. Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM. Int J Card 106 (2006) 16-20
24. Bard R.L., Kalsi H., Rubenfire M.D., and Brook R.D. Effect of carotid atherosclerosis screening on risk stratification during primary cardiovascular disease prevention. Am J Cardiol 93 (2004) 1030-1032
25. Magyar M.T., Szikszai Z., Balla J., et al. Early-onset carotid atherosclerosis is associated with increased intima-media thickness and elevated serum levels of inflammatory markers. Stroke 34 (2003) 58-63
26. Hashimoto H., Kitagawa K., Hougaku H., et al. C-reactive protein is an indipendent predictor of the rate of increase in early carotid atherosclerosis. Circulation 104 (2001) 63-67
27. Corrado E., Rizzo M., Muratori I., Coppola G., and Novo S. Association of elevated fibrinogen and C-reactive protein levels with carotid lesions in patients with newly diagnosed hypertension or type-II diabetes. Arch Med Res 37 (2006) 1004-1009
28. Sviridov D., and Nestel P.J. Genetic factors affecting HDL levels, structure, metabolism and function. Curr Opin Lipidol 18 (2007) 157-163
29. Ernst E., and Resch K.L. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 118 (1993) 956-963
30. Koenig W. Fibrinogen in cardiovascular disease: an update. Thromb Haemost 89 (2003) 601-609
31. Kakafika A.I., Liberopoulos E.N., and Mikhailidis D.P. Fibrinogen: a predictor of vascular disease. Curr Pharm Des 13 (2007) 1647-1659
32. Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 24 (2006) 33-50
33. Jialal D., Stein D., Balis D., Grundy S., Adams-Huet B., and Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A Reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103 (2001) 1933-1935
34. Atalar E., Ozmen F., Haznedaroglu I., et al. Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease. Int J Cardiol 84 (2002) 227-231